Two CD­MOs come to­geth­er as they look to ex­pand their reach in cell ther­a­py man­u­fac­tur­ing

As the cell ther­a­py field has ma­tured, the man­u­fac­tur­ing of such ther­a­pies be­comes a greater fo­cus for com­pa­nies small and large. Amid this growth, two CD­MOs have come to­geth­er in a merg­er to ex­pand their reach.

Lykan Bio­science, based in Mass­a­chu­setts, and RoslinCT, based in Ed­in­burgh, UK, will be­come a sin­gle ad­vanced ther­a­pies CD­MO. The new­ly com­bined group will of­fer process de­vel­op­ment ex­per­tise as well as cGMP man­u­fac­tur­ing for a broad range of au­tol­o­gous and al­lo­gene­ic cell ther­a­pies, along with gene edit­ing and in­duced pluripo­tent stem cell (iP­SC) ca­pa­bil­i­ties for cell ther­a­py de­vel­op­ment. Fi­nan­cial terms of the deal were not dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER